Hematopoietic stem cell transplant (HSCT) is an established therapy for various malignant and nonmalignant disorders in adults. Despite significant improvement in supportive care, HSCT continues to be associated with significant morbidity and mortality. Pericardial effusion (PE) is a known complication of HSCT that can result in significant morbidity and even death by causing acute cardiac tamponade. 1, 2 The exact incidence and risk factors are not well established, but retrospective reviews report PE occurring in 0.2-19% of HSCT patients. 1, 3, 4 Age, gender, disease risk, conditioning regimen, neutrophil engraftment, relapse, GVHD, GVHD prophylaxis, donor type and CMV viremias have been suggested as potential risk factors. 1, [4] [5] [6] [7] The initial symptoms of PE can be non-specific, thus early recognition of PE may allow us to further optimize care and improve outcomes.
In our retrospective clinical practice, we observed that patients receiving a myeloablative conditioning regimen were more likely to develop early pericardial effusion (PE) (within 100 days of transplantation) in auto-hematopoietic stem cell transplant (auto-HSCT). Patients who relapsed were more likely to have early PE in allo-HSCT. Patients with longer neutrophil engraftment using immunosuppressive drugs other than cyclosporine were more likely to develop late-onset PE (beyond 100 days post transplantation) in allo-HSCT. Patients with PE tend to have inferior overall survival (OS) and higher treatment-related mortality (TRM) than patients without PE. Death rate due to infection or GVHD was higher in PE patients than those without PE.
Our goal was to determine the incidence and risk factors of PE and correlate it with mortality over the subsequent 5 years. Consecutive adult patients (age ⩾ 18 years) who received HSCT at the Hematology Department in Tongji Hospital between March 2003 and January 2014 were included in this study. All available medical records, notes, imaging reports, correspondence and autopsy reports were reviewed for patients who remained for study analysis. PE was diagnosed if post-transplant echocardiography or CT scan showed a new or increased presence of clear space between the visceral and parietal pericardium, reflecting an accumulation of fluid.
8 Significant PE was defined as patients who were symptomatic, had clinical or echocardiographic evidence of tamponade, were treated with pericardiocentesis, or if the PE was reported as moderate or large PE on echocardiogram. Patients had routine physical examination of cardiomegaly on CT scan and echocardiogram before transplantation, at day 30 post transplant or as clinically indicated. If needed, additional examination was performed. The majority of patients were diagnosed with PE as an incidental finding of cardiomegaly on CT scan or echocardiogram performed for other reasons. None of the patients who developed PE after HSCT had a history of PE before their transplant. All CT scan and echocardiography records were reassessed by three independent radiologists to make the results more accurate, regardless of PE. Definitions and statistics were provided in the Supplementary material.
A total of 321 adult HSCT patients were identified, including 110 autologous transplant recipients. Patients were excluded from this analysis if they received more than one transplant (n = 5). As 5 patients received more than one transplant, 108 autologous and 208 allo-HSCT patients remained for the study analysis. Among the 316 HSCT recipients, the median age at HSCT was 33.0 years (17.0-63.0 years), and male-to-female ratio was 1. Of the 69 patients, 49 (70.1%) patients developed small PE, 13 (18.8%) developed moderate PE, leaving 7 (10.1%) patients with large PE. Among the seven patients with large PE, only one patient had obvious clinical symptoms and needed pericardiocentesis. Left ventricular ejection fraction was different between PE patients and those without PE (62.36 ± 5.24% vs 68.72 ± 6.70%, P o0.005). Most patients were treated conservatively with aggressive diueresis, β-blockers and spironolactone in our center, only one patient with a large amount of PE underwent pericardiocentesis. In the entire group of patients with PE, 33 died (47.8%); however, none died directly of pericardial tamponade and/or surgical therapeutic intervention. In all, 4 patients died of relapse, 14 patients infection, 5 patients GVHD, 7 patients both infection and GVHD and 3 patients cerebral hemorrhage.
As mentioned earlier, other studies have suggested donor source, GVHD, infection, relapse and disease risk as risk factors for developing PE post HSCT. 4, 6, [9] [10] [11] We evaluated these and other risk factors using univariate and multivariate analysis. Risk factors typically associated with worse prognosis were also associated with risk of developing PE. Because most patients (97.1%) received PBSC in our center and that only one (1.4%) PE patient received chest irradiation in our center, we did not include those as risk factors. In a univariate analysis, myeloablative conditioning regimen (hazard ratio (HR) 8.080, 95% confidence interval (CI) 1.041-62.735; P = 0.046) and relapse (HR 2.460, 95% CI 1.236-4.897; P = 0.010) were the two significant risk factors for developing early-onset PE in autologous and allo-HSCT, respectively. Disease risk (HR 2.869, 95% CI 1.084-7.594; P = 0.034), neutrophil engraftment (HR 4.801: 1.688-13.654; P = 0.003) and GVHD prophylaxis (HR 4.083, 95% CI 1.486-11.220; P = 0.006) were risk factors for developing late-onset PE in allo-HSCT. In multivariate analysis, neutrophil engraftment (HR 4.582, 95% CI 1.543-13.606; P = 0.006) and GVHD prophylaxis (HR 4.456: 95% CI 1.552-12.797; P = 0.005) were risk factors for developing late-onset PE in allo-HSCT. Only three patients developed PE beyond 100 days in auto-HSCT and therefore not been analysed, all of whom received a myeloablative condition regimen. Details are shown in Table 1 .
Neier et al. 7 suggested that PE is a significant risk factor for posttransplant mortality. We evaluated the effect of PE and other factors on 5-year OS and 5-year TRM using univariate and multivariate analysis. In univariate analysis, PE was not the risk factor affecting the 5-year OS and 5-year TRM in auto-HSCT. Univariate analysis of risk factors affecting the 5-year OS and 5-year TRM post PE in allogeneic HCST included disease risk (HR 2.055: 95% CI 1.185-3.564; P = 0.010 and HR 2.186: 95% CI 1.190-4.016; P = 0.012, respectively ), conditioning regimen (HR 2.254: 95% CI 1.129-4.502; P = 0.021 and HR 2.338: 95% CI 1.082-5.053; P = 0.031, respectively), PE (HR 1.112: 95% CI 1.047-1.182; P = 0.001 and HR 1.134: 95% CI 1.053-1.222; P = 0.001, respectively) and aGVHD (HR 2.585: 95% CI 1.487-4.493; P = 0.001 and HR 2.538: 95% CI 1.380-4.667; P = 0.003, respectively). In multivariate analysis, PE remained significant factor affecting the 5-year OS (HR 1.074: 95% CI 1.010-1.142; P = 0.022) and 5-year TRM (HR 1.096: 95% CI 1.019-1.179; P = 0.014) post transplantation in allogeneic HCST. Besides, aGVHD (HR 1.978: 95% CI 1.106-3.538; P = 0.022) was another significant risk factor for lower 5-year OS. Disease risk (HR 1.096: 95% CI 1.019-1.179; P = 0.014) and aGVHD (HR 1.998: 95% CI 1.063-3.757;P = 0.032) were also risk factors for higher 5-year TRM. Details are shown in Table 1 .The presence or absence of PE had a significant impact on 5-year OS (74.9 vs 30.0%, P o 0.0001, Figure 1e ) and 5-year TRM after allo-HSCT (66.1 vs 18.9%, P o 0.0001, Figure 1g ). Further analysis about death due to GVHD or infection also showed great differences between patients with and without PE (65.7 vs 22.2%, P o 0.0001, Figure 1h ). On the contrary, we did not find significant differences between patients with and without PE due to relapse or progression (18.8 vs 7.7%, P = 0.1212, Figure 1f) .
To the authors' knowledge, this is the largest study specifically aimed to evaluate the effects of PE on survival following adult HSCT and to identify patients at higher risk. Results of this study suggest that post-transplant PE could be regarded as a new (f) Probability of 5-year TRM following HSCT in adult recipients as determined by cumulative incidence estimates (P o0.0001). (g) Probability of relapse or progression related death following HSCT in adult recipients as determined by cumulative incidence estimates (P = 0.1212). (h) Probability of death due to GVHD or infection following HSCT in adult recipients as determined by cumulative incidence estimates (P o0.0001). Letter to the Editor predictor for inferior survival and high mortality following adult allo-HSCT. Besides, significant PE with or without cardiac tamponade is a rare but potentially life-threatening complication following HSCT. [12] [13] [14] [15] While the mechanisms underlying the negative influence of post-transplant PE on survival and mortality remain to be elucidated, we are convinced that it is imperative to initiate closer screening for the development of PE. Patients diagnosed with a significant PE should be promptly evaluated by a cardiologist.
We acknowledge that our study is limited to its retrospective nature and that there were no standardized time points for performing routine CT scan or echocardiograms. Therefore, more randomized prospective studies are required to investigate the etiology of PE and determine the best treatment approach for PE after HSCT.
